The firm is an Asia-based venture capital investor focused on early-stage healthcare and life sciences companies. The firm manages multiple healthcare-focused investment funds and primarily invests from company formation and Seed through Series A and other early venture financing rounds. The firm can lead investments or participate alongside other institutional investors and takes a hands-on approach to building and supporting emerging healthcare businesses. The firm invests globally, with a particular emphasis on companies in their region and the United States and opportunities connecting the two life sciences ecosystems.

The firm invests across therapeutics, medical devices, diagnostics, digital health, and healthcare services, with a strong emphasis on innovative therapeutic platforms and drug discovery technologies. Within therapeutics, the firm is broadly agnostic across modalities and indications, prioritizing differentiated science addressing significant unmet medical needs. The firm is comfortable investing at the earliest stages of development, including platform technologies at proof-of-concept stage. For asset-focused therapeutic opportunities, the firm generally seeks sufficient preclinical validation to support the underlying scientific hypothesis. The firm also evaluates innovative medical technologies, molecular diagnostics, and technology-enabled healthcare solutions with strong commercial potential.

From a company and management team perspective, the firm seeks entrepreneurs and scientific founders developing differentiated healthcare technologies with strong scientific foundations and significant market opportunities. The firm actively supports portfolio companies through R&D and business strategy, management recruitment, investor syndication, strategic partnerships, and business development. The firm leverages relationships with pharmaceutical companies, academic institutions, healthcare organizations, and institutional investors to facilitate company growth and cross-border expansion. The firm can serve as a lead investor or co-investor and may seek board representation where appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A U.S.-based angel investment group invests in seed-stage life sciences and technology companies. The firm’s typical initial investment ranges from $100,000 to $250,000, structured as either secured convertible debt with interest and a discount upon conversion to preferred shares, or direct investments in preferred equity. Geographically, the firm focuses on opportunities in the United States, Canada, and Israel. 

Within life sciences, the investor is primarily interested in early-stage medical devices and diagnostics. The firm is flexible regarding technology types and therapeutic indications, provided the solutions address meaningful medical needs. The investor also considers therapeutics companies, with a preference for those that have reached the early clinical stage. The firm generally avoids investments in purely digital applications. 

The firm does not have specific company or management team requirements and can provide active advisory support to portfolio companies as needed. The investor prefers to co-invest alongside larger investment groups rather than lead financing rounds and seeks companies with a clear potential exit pathway within three to five years. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A Canada-based, family-owned investment firm with a background in manufacturing invests in both public and private companies across a variety of industries, including healthcare and biotechnology. For private investments, the firm’s typical check size ranges from $1 million to $5 million. The firm generally prefers participating in investment rounds rather than leading them and primarily focuses on opportunities in North America. 

The firm is industry-agnostic and open to opportunities across medtech, biotech, digital health, and healthtech. The investor prefers companies that are closer to commercialization rather than those in the preclinical or early clinical stages, where it can leverage its expertise in commercialization and revenue growth to support portfolio companies. 

The firm does not have specific company or management team requirements, although founding teams with successful track records are viewed favorably.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A Europe-based venture capital firm founded by entrepreneurs with extensive life sciences and biotechnology experience focuses exclusively on novel therapeutics. The firm invests at the earliest stages of development, from Seed through late preclinical programs, typically supporting assets through clinical proof of concept and seeking exits following meaningful clinical validation. The firm is currently investing from an existing fund primarily focused on Europe and is nearing the end of its deployment period. The investor plans to raise its next fund in the near term, with an anticipated stronger focus on U.S. opportunities. 

The firm typically makes initial equity investments ranging from $3 million to $5 million and may also consider convertible loan structures where appropriate. It has the capacity to invest approximately $15 million to $20 million per company over the life of an investment. The firm participates in both company creation and investment syndicates alongside other specialist biotech investors. 

The investor focuses exclusively on therapeutics and is indication- and modality-agnostic. It seeks novel drug candidates with strong scientific rationale, differentiated mechanisms of action, significant unmet medical needs, and high commercial potential. The firm’s primary considerations are the stage of development, scientific differentiation, and commercial opportunity rather than specific therapeutic areas or modalities. 

The firm sources opportunities through its global network of biotech founders, academic researchers, and entrepreneurial management teams. Following investment, it works closely with portfolio companies to execute R&D strategies, optimize capital allocation, and prepare for future financing rounds or strategic transactions. While historically focused on Europe, the firm takes a geographically opportunistic approach and evaluates opportunities based on scientific merit, valuation, and potential risk-adjusted returns. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A U.S.-based corporate venture capital firm backed by a Japanese chemical manufacturer is seeking investment opportunities in emerging markets, including life sciences and healthcare. The firm invests from Seed stage onward, with a preference for Series A and B opportunities, while remaining open to later-stage investments on a case-by-case basis. Investment amounts range from several hundred thousand to several million dollars, with the flexibility to make follow-on investments. 

The firm considers opportunities globally and works closely with its regional investment teams in Japan and East Asia to evaluate cross-border investments. 

While the firm has a background in chemicals and materials, it does not require portfolio companies to be materials-focused. Areas of interest include diagnostic platforms, AI and AI-enabled drug discovery, biotech tools, and other physical technologies, particularly those incorporating consumables or offering recurring consumables revenue opportunities. The firm is disease-agnostic and prefers companies that have demonstrated proof of concept or other evidence of technical feasibility and/or market potential. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A U.S.-based venture capital firm invests in early-stage neuropsychiatric and mental health opportunities. The firm primarily invests from Pre-Seed through Series A, with initial checks typically ranging from $50K–$1M and capacity for follow-on investment. The firm is comfortable serving as the first institutional investor and can lead or co-invest alongside other investors. Investments may be structured through traditional equity financings or SAFEs. The firm primarily targets U.S.-based companies while remaining open to opportunities globally.  

The firm invests in therapeutics and technologies addressing neuropsychiatric conditions, mental health, and general wellness. Areas of interest include psychedelic medicine, brain-computer interfaces, therapeutic platforms, precision diagnostics, and other technologies addressing neurological and psychiatric conditions. For biotechnology and therapeutics opportunities, the firm generally prefers assets that are at or approaching the IND stage. For medical technology opportunities, the firm is comfortable engaging earlier in the development process.  

From a company and management team perspective, the firm does not impose strict requirements regarding team composition. The firm has a strong preference for founders with prior pharmaceutical or biotechnology industry experience or a demonstrated track record of successful entrepreneurship. The firm may seek a board seat or observer position on a case-by-case basis and takes a flexible approach to governance depending on the company’s stage and financing structure. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a U.S.-based venture capital investor focused on Seed through growth-stage deep-tech companies, including opportunities across healthcare. The firm invests through direct and special-purpose investment structures and can access matching capital of up to $10M for qualifying companies willing to establish operations in a designated U.S. innovation ecosystem. The firm primarily targets companies with differentiated technologies and evidence of meaningful technical or commercial validation. 

Within healthcare, the firm focuses primarily on healthtech, including digital health and medical technology. For therapeutics, the firm selectively considers companies addressing compelling disease areas through novel technologies and generally requires programs to have completed Phase I development or otherwise achieved substantial technical and clinical de-risking. For digital health opportunities, the firm requires demonstrated customer traction and a minimum level of commercial revenue. Pre-revenue pharmaceutical companies may be considered when meaningful alternative indicators of traction and validation can be demonstrated.  

From a company and management team perspective, the firm seeks companies that can demonstrate clear evidence of technology validation, market traction, or clinical de-risking appropriate to their sector and development stage. The firm takes an active governance approach and requires a board seat as part of its investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.